Gland Pharma Return on Equity (ROE) History

Gland Pharma Ltd Return on Equity

The Gland Pharma Ltd Return on Equity is a key financial metric used by investors to evaluate Gland Pharma Ltd's valuation, profitability, and overall financial performance. Tracking the Gland Pharma Ltd Return on Equity helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.

Gland Pharma Ltd (NSE: GLAND, BSE: 543245) is currently trading at ₹1780.80, with a market capitalization of ₹293.21B. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Gland Pharma Ltd Return on Equity is essential for fundamental analysis.

Gland Pharma Ltd Return on Equity Current Value

The current Gland Pharma Ltd Return on Equity stands at 7.82.

The Gland Pharma Ltd Return on Equity has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.

Gland Pharma Ltd Return on Equity Historical Trend

The Gland Pharma Ltd Return on Equity has shown the following historical trend:

• 2024: 7.82
• 2023: 9.26
• 2022: 10.33
• 2021: 18.55
• 2020: 20.88

The decline in Gland Pharma Ltd Return on Equity indicates improving financial efficiency or better earnings growth.

What Gland Pharma Ltd Return on Equity Indicates for Investors

The Gland Pharma Ltd Return on Equity plays a crucial role in understanding the company's financial health and valuation.

ROE indicates how efficiently the company generates returns for shareholders.

Gland Pharma Ltd Return on Equity Analysis Summary

The Gland Pharma Ltd Return on Equity remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Gland Pharma Ltd Return on Equity should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.

Regular tracking of Gland Pharma Ltd Return on Equity helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.